Press Releases2019-02-14T10:57:14-06:00

Press Releases

ELIAS autologous prescription product exceeds expectations for trial safety and efficacy

Olathe, Kan., July 31, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, shared promising preliminary canine osteosarcoma results for its cancer immunotherapy at the 2018 American College of Veterinary Internal Medicine (ACVIM) Forum in June. The study indicated its new ELIAS autologous cancer vaccine, featuring a patented combination of vaccine and T cell infusion approach, demonstrated impressive survival times and minimal side effects. This cancer immunotherapeutic is being distributed as an experimental product under 9 CFR 103.3 to veterinarians treating dogs diagnosed with cancer. Efficacy and safety have not been [...]

July 31st, 2018|

ELIAS Animal Health Cancer Immunotherapy selected for state of the art presentation at VCS Mid‐Year Conference

Olathe, Kan., Feb. 12, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has been selected by the Veterinary Cancer Society (VCS) for a “State of the Art” presentation at its Mid‐Year Conference in Anchorage, Alaska, March 10‐13. The mid‐year conference is focused on immunotherapy. Brenda Phillips, D.V.M., Dipl. ACVIM (Oncology) will present “T cell‐mediated immunotherapy for common canine cancers” during the state of the art presentation on Sunday, March 11. Dr. Phillips is a board‐certified specialist in medical oncology, practicing with Veterinary Specialty Hospital in San Diego, Calif. The clinical [...]

February 12th, 2018|

ELIAS Animal Health adds clinical trial site for ECI™ for the treatment of canine osteosarcoma

ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, is offering a fourth site for its clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™) as a treatment for newly- diagnosed appendicular osteosarcoma in dogs. The objective of this clinical trial is to determine whether ECI™ used in combination with surgery produces better outcomes than treatment with surgery alone. Efficacy will be determined by patient survival and comparing the outcomes to historical control data. The trial will be conducted at the Veterinary Specialty Hospital of San Diego. ELIAS Animal [...]

November 15th, 2016|
Go to Top